GlassScriptPhysician profile
Preethi Prasad
NPI 1457612483
$2,291.90
in general payments reported to CMS, 2019-2025
29 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.58 · 2024: $1,154 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $347.21 | 2024-2025 | |
| Celgene Corporation | $287.53 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $181.09 | 2024-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $161.25 | 2024-2025 | Enhertu, Tagrisso |
| Aveo Pharmaceuticals, INC. | $125.47 | 2024-2025 | |
| Lilly USA, LLC | $117.69 | 2024-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $94.57 | 2025 | |
| Eisai INC. | $92.61 | 2024-2025 | |
| Pharmaessentia USA Corporation | $87.14 | 2024 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $75.08 | 2019-2024 | Iclusig |
| Janssen Biotech, INC. | $67.40 | 2024 | Erleada, Akeega, Imbruvica |
| Merck Sharp & Dohme LLC | $60.42 | 2024 | Keytruda, Welireg, Reblozyl |
| Abbvie INC. | $55.64 | 2024-2025 | |
| Puma Biotechnology, INC. | $54.16 | 2024-2025 | |
| Daiichi Sankyo INC. | $52.57 | 2025 | Enhertu |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.83 | 2024-2025 | Xospata, Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $48.44 | 2024-2025 | |
| Array Biopharma INC | $48.12 | 2024 | Mektovi, Braftovi, Tukysa |
| Shield Therapeutics INC | $44.51 | 2024-2025 | |
| Boston Scientific Corporation | $44.49 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Myriad Genetic Laboratories, INC. | $33.67 | 2025 | Myrisk |
| Pharmacosmos Therapeutics INC. | $26.58 | 2025 | Monoferric |
| Blueprint Medicines Corporation | $25.71 | 2024 | Ayvakit |
| Emd Serono, INC. | $24.03 | 2024 | |
| Glaxosmithkline, LLC. | $19.99 | 2024 | Jemperli |
| Janssen Pharmaceuticals, INC | $19.50 | 2024 | Tecvayli |
| Incyte Corporation | $19.18 | 2025 | Monjuvi |
| Taiho Oncology, INC. | $15.07 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.95 | 2025 | Talvey, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.